Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials

Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials

Recent major phase III trials led to the approval of immune checkpoint inhibitors (ipilimumab, pembrolizumab, and nivolumab) in metastatic malignant melanoma (MM). We aim to assess whether median progression-free survival, and 1 and 2-year overall survival (OS) rates are reliable surrogate endpoints...

Full description

Bibliographic Details
Main Authors: Petrelli, Fausto, Coinu, Andrea, Cabiddu, Mary, Borgonovo, Karen, Ghilardi, Mara, Lonati, Veronica, Barni, Sandro
Format: Online
Language:English
Published: Wolters Kluwer Health 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937921/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937921/

Similar Items